Updated: FDA panel backs Pfizer's RSV maternal vaccine, despite debate over safety
An FDA independent advisory panel of infectious-disease and vaccine experts voted in general support of recommending Pfizer’s RSV vaccine, Abrysvo, to protect infants from the respiratory virus.
After listening to presentations from scientists from the Centers for Disease Control and Prevention, the FDA, and Pfizer, the panel voted on two questions if the data support the effectiveness and safety of the vaccine for this population. The panel unanimously voted 14-0 in support of efficacy, and 10-4 in favor of the safety data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.